article thumbnail

Tapping the potential applications of mHealth

The Health Policy Exchange

mHealth applications can complement and expand care provided at traditional face-to-face visits, and exploring their untapped potential to improve health in the U.S. and abroad was the topic of a recent Georgetown University Health Policy Seminar. How can we avoid creating "digital divides" that could worsen health disparities?

article thumbnail

The Massachusetts Avenue of health reform

The Health Policy Exchange

This month's Georgetown University Health Policy Seminar explored the politics of "Romneycare," a state-level health reform which in many ways made possible the future Affordable Care Act. It was one thing to ask drivers to buy car insurance. Owning a car is a choice. Together, Romney and Kennedy approached the George W.

Insurance 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nutrition and dietary guidelines: stirring the (policy) pot

The Health Policy Exchange

At first glance, federal nutrition policy seemed to be an unusual topic for our Georgetown Health Policy Seminar for family physicians. As described in a recent JAMA Internal Medicine editorial , future doctors receive little formal instruction about healthy dietary habits. and MyPlate. Kenny Lin, MD, MPH Director, Robert L.

article thumbnail

Medicaid expansion is in the eye of the beholder

The Health Policy Exchange

To the ACA's detractors, Medicaid expansion is a hostile government takeover that must be opposed in principle, regardless of potential benefits of an infusion of federal dollars. In fiscal year 2011, Medicaid spending totaled $414 billion, with two-thirds going to services for disabled elderly persons.

Insurance 130
article thumbnail

Biased research, aggressive sales, harmful drugs

The Health Policy Exchange

Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. government agencies do more to protect patients from the effects of biased research and aggressive sales tactics for newly marketed drugs? Could the FDA and other U.S.